These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 15901610

  • 21. Inhaled glucocorticoids in COPD: immortal time bias.
    Sin DD, Man SF, Tu JV.
    Am J Respir Crit Care Med; 2003 Jul 01; 168(1):126-7. PubMed ID: 12826595
    [No Abstract] [Full Text] [Related]

  • 22. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis.
    Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW.
    Thorax; 2013 Mar 01; 68(3):256-62. PubMed ID: 22781123
    [Abstract] [Full Text] [Related]

  • 23. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
    Lee TA, Schumock GT, Bartle B, Pickard AS.
    Pharmacotherapy; 2009 Sep 01; 29(9):1039-53. PubMed ID: 19698009
    [Abstract] [Full Text] [Related]

  • 24. Inhaled corticosteroids in chronic obstructive pulmonary disease.
    Suissa S, McGhan R, Niewoehner D, Make B.
    Proc Am Thorac Soc; 2007 Oct 01; 4(7):535-42. PubMed ID: 17878466
    [Abstract] [Full Text] [Related]

  • 25. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC, Lau H, La HO, Choi IS, Geba GP.
    Curr Med Res Opin; 2010 Feb 01; 26(2):297-306. PubMed ID: 19961283
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 01; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis.
    Flynn RW, MacDonald TM, Hapca A, MacKenzie IS, Schembri S.
    Respir Res; 2014 Nov 19; 15(1):141. PubMed ID: 25407604
    [Abstract] [Full Text] [Related]

  • 31. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).
    Cecere LM, Slatore CG, Uman JE, Evans LE, Udris EM, Bryson CL, Au DH.
    COPD; 2012 Jun 19; 9(3):251-8. PubMed ID: 22497533
    [Abstract] [Full Text] [Related]

  • 32. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis.
    Loke YK, Kwok CS, Wong JM, Sankaran P, Myint PK.
    Int J Clin Pract; 2013 May 19; 67(5):477-87. PubMed ID: 23574107
    [Abstract] [Full Text] [Related]

  • 33. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan.
    Huang CC, Chan WL, Chen YC, Chen TJ, Chou KT, Lin SJ, Chen JW, Leu HB.
    Clin Ther; 2011 Oct 19; 33(10):1365-70. PubMed ID: 21962452
    [Abstract] [Full Text] [Related]

  • 34. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia.
    Sellares J, López-Giraldo A, Lucena C, Cilloniz C, Amaro R, Polverino E, Ferrer M, Menéndez R, Mensa J, Torres A.
    Am J Respir Crit Care Med; 2013 Jun 01; 187(11):1241-8. PubMed ID: 23590264
    [Abstract] [Full Text] [Related]

  • 35. Economic impact of using inhaled corticosteroids without prior exacerbation among elderly patients with chronic obstructive pulmonary disorder.
    Chen S, Plauschinat CA, Wu N, Fraser K, Boulanger L.
    J Med Econ; 2011 Jun 01; 14(4):458-62. PubMed ID: 21651427
    [Abstract] [Full Text] [Related]

  • 36. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
    Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM.
    Respir Med; 2007 Jul 01; 101(7):1398-405. PubMed ID: 17368011
    [Abstract] [Full Text] [Related]

  • 37. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease.
    Pujades-Rodríguez M, Smith CJ, Hubbard RB.
    QJM; 2007 Aug 01; 100(8):509-17. PubMed ID: 17609226
    [Abstract] [Full Text] [Related]

  • 38. Statin use is associated with reduced mortality in COPD.
    Søyseth V, Brekke PH, Smith P, Omland T.
    Eur Respir J; 2007 Feb 01; 29(2):279-83. PubMed ID: 17050558
    [Abstract] [Full Text] [Related]

  • 39. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug 01; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 40. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias.
    Suissa S.
    Am J Respir Crit Care Med; 2006 Feb 15; 173(4):464; author reply 464-5. PubMed ID: 16467177
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.